未接受过放疗的头颈癌患者辅助高剂量率近距离放疗的前瞻性注册试验:20年数据
该前瞻性注册试验自2000年至2018年纳入152例接受手术的头颈癌患者,分别行辅助高剂量率近距离放疗单独(n=32)或联合外照射放疗±化疗(n=120)。中位随访8.1年,5年局部控制率85.5%、区域控制率74.9%、无病生存率54.9%、总生存率62.2%;26.3%发生RTOG≥3级不良事件,主要为软组织坏死(11.2%)和放射性骨坏死(6.6%)。作者认为辅助高剂量率近距离放疗单独或联合外照射放疗是合适的治疗选择,毒性和局部区域控制与标准化疗放疗相当。
要点
- 152例术后头颈癌患者接受辅助高剂量率近距离放疗单独(n=32)或联合外照射放疗±化疗(n=120)。
- 5年局部控制率85.5%、区域控制率74.9%、无病生存率54.9%、总生存率62.2%。
- 26.3%发生RTOG≥3级不良事件,软组织坏死11.2%、放射性骨坏死6.6%。
核心结论
- 辅助高剂量率近距离放疗单独或联合外照射放疗是适合接受术后放疗或化疗放疗的头颈癌患者的充分治疗选择。
- 毒性和局部区域控制结果与标准化疗放疗相当。
- 研究识别出在高危临床靶区不超过15 cm³且EQD2-DVH TV100剂量低于87 Gy、下颌骨2cm³剂量低于61 Gy的条件下,可能从辅助高剂量率近距离放疗中获益(毒性降低)的部分患者。
研究设计与样本
- 前瞻性注册试验,2000年至2018年纳入152例诊断为头颈癌并接受手术及辅助高剂量率近距离放疗的患者。
- 辅助高剂量率近距离放疗单独组32例,联合外照射放疗±化疗组120例。
- 近距离放疗单独组接受32或40 Gy,分8或10次,每日两次。
- 联合模式组接受高剂量率近距离放疗16或24 Gy,分4-6次,每日两次,随后外照射放疗45 Gy分25次±化疗。
主要发现
- 中位随访8.1年(范围0.1-21.6年)。
- 40例(26.3%)发生RTOG≥3级不良事件,主要为软组织坏死(11.2%)和放射性骨坏死(6.6%)。
- 5年局部控制率为85.5%,区域控制率为74.9%。
- 5年无病生存率为54.9%,总生存率为62.2%。
关键数值与推荐
- 辅助高剂量率近距离放疗单独组剂量为32或40 Gy,分8或10次,每日两次。
- 联合模式组高剂量率近距离放疗剂量为16或24 Gy,分4-6次,每日两次,随后外照射放疗45 Gy分25次±化疗。
- 高危临床靶区不超过15 cm³且EQD2-DVH TV100剂量低于87 Gy、下颌骨2cm³剂量低于61 Gy的患者可能从辅助高剂量率近距离放疗中获益(毒性降低)。
临床怎么用
- 作者认为辅助高剂量率近距离放疗单独或联合外照射放疗是适合接受术后放疗或化疗放疗的头颈癌患者的充分治疗选择。
- 作者认为在高危临床靶区不超过15 cm³且EQD2-DVH TV100剂量低于87 Gy、下颌骨2cm³剂量低于61 Gy的条件下,部分患者可能从辅助高剂量率近距离放疗中获益(毒性降低)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Full-dose postoperative external beam radiation therapy (EBRT)/chemoradiation is the standard of care in patients with resected, unirradiated head and neck cancer (HNC). This study aims to determine the long-term results of adjuvant high-dose rate (HDR) brachytherapy ± intermediate-dose postoperative external beam radiation therapy (EBRT)/chemoradiation in this HNC patient population. MATERIALS AND METHODS: From 2000 to 2018, a total of 152 patients diagnosed with HNC were treated with surgery and adjuvant HDR brachytherapy alone (n = 32) or combined with EBRT ± chemotherapy (n = 120). Patients treated with brachytherapy alone received 32 or 40 Gy in 8 or 10 b.i.d. fractions. Combined modality patients received 16 or 24 Gy of HDR brachytherapy in 4-6 b.i.d. fractions followed by EBRT 45 Gy in 25 fractions ± chemotherapy. RESULTS: Median follow-up was 8.1 years (range, 0.1-21.6). Forty patients (26.3%) developed RTOG grade ≥ 3 adverse events, mainly soft tissue necrosis (11.2%) and osteoradionecrosis (6.6%). The 5-year local and locoregional control rates were 85.5% and 74.9%, respectively. Five-year disease-free survival and overall survival rates were 54.9% and 62.2%, respectively. CONCLUSION: Adjuvant HDR brachytherapy alone or combined with EBRT is an adequate treatment option for HNC patients who are candidates to receive postoperative radiation/chemoradiation. The results obtained in terms of toxicity and locoregional control are comparable to standard chemoradiation. In addition, this study identifies a subset of patients that may benefit from adjuvant HDR in terms of reduced toxicity, provided that the high-risk CTV does not exceed 15 cm3 and is treated to EQD2-DVH TV100 doses of less than 87 Gy, together with a mandible2cm3 of less than 61 Gy.
引用
- García-Consuegra A, Gimeno-Morales M, Cambeiro M, et al. Prospective Registry Trial of Adjuvant High-Dose Rate Brachytherapy in Unirradiated Head and Neck Cancer: 20-Year Data. Head Neck. 2025. PMID: 40062517. doi:10.1002/hed.28131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。